Shaanxi Micot Pharmaceutical Technology's (HKG:2335) research results for XTL6001 have been accepted for presentation at multiple academic conferences in the fields of diabetes, metabolic diseases, and nephrology.
Following an initial presentation at the American Diabetes Association, additional analysis will be presented at the upcoming European Association for the Study of Diabetes (EASD) and American Society of Nephrology (ASN) annual meetings, according to a Monday Hong Kong bourse filing.
Two research abstracts will be featured at the 62nd annual meeting of the EASD, with one to be presented at ASN Kidney Week 2026.